Related Experiment Videos
The interaction of CD4 with HIV-1 gp120
S L Silberman1, S J Goldman, D B Mitchell
1Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
Insights
Small molecules called CPFs block the interaction between CD4 and HIV-1's gp120 protein. This inhibition prevents HIV-1 infection and may help restore T cell function in AIDS patients.
Area of Science:
- Immunology
- Virology
- Molecular Biology
Background:
- CD4 is a cell surface glycoprotein crucial for T cell responses and serves as the primary receptor for HIV-1.
- HIV-1 infection begins when the viral envelope glycoprotein gp120 binds to the CD4 receptor.
- The gp120 binding to CD4 can inhibit T cell function and contribute to immunosuppression in AIDS.
Purpose of the Study:
- To develop novel small molecules that inhibit the interaction between HIV-1 gp120 and the CD4 receptor.
- To assess the efficacy of these small molecules in blocking viral entry and infectivity.
Main Methods:
- Synthesis of small molecules, termed CD4-binding protein fragments (CPFs).
- In vitro assays to evaluate the ability of CPFs to inhibit gp120 binding to CD4.
- Assessment of CPF's effect on HIV-1 infectivity.
Main Results:
- CPFs were successfully synthesized and demonstrated specific binding to gp120.
- CPFs effectively inhibited the interaction between gp120 and CD4.
- CPFs significantly reduced HIV-1 infectivity in cell-based assays.
Conclusions:
- CPFs represent a promising therapeutic strategy by targeting the critical CD4-gp120 interaction.
- These molecules offer a potential approach to inhibit HIV-1 entry and mitigate T cell dysfunction in HIV-1 infection.
Abstract:
CD4 is an integral cell surface glycoprotein that is able to enhance T cell specific antigen responses when it interacts with its physiological ligand, class II major histocompatibility (MHC) molecules. In addition, CD4 is a specific cell-surface receptor for the human immunodeficiency virus-1 (HIV-1). Infection by HIV-1 is initiated by the binding of the envelope glycoprotein, gp120, to the first domain of CD4. The binding of CD4 to class II MHC is inhibited by gp120, one possible mechanism for immunosuppression in AIDS patients. In addition, the CD4/gp120 interaction may directly inhibit T cell function. Recently we have synthesized small molecules (CPFs) that specifically inhibit this interaction. CPFs bind to gp120 and prevent the binding of gp120 to CD4, and also inhibit the infectivity of HIV-1.